ProFactor Pharma

Transforming treatment availability for Haemophilia A

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia A.

Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

More About Us

PFP licenses FVIII technology to PT Bio Farma (Persero) of Indonesia for potential $1.36bn ASEAN-6 & India territories

Learn More

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Learn About Haemophilia

Recent News

Eugenia Wachters appointed Chief Operating Officer at ProFactor Pharma

Jul 10, 2023 | News

ProFactor Pharma Ltd (PFP) is excited to welcome Eugenia Wachters, who joined the company as Chief Operating Officer on 1st July 2023. Eugenia will be responsible for leading the company’s business operations, working closely with the PFP Executive team and Board...

World Hemophilia Day

Apr 19, 2023 | News

The World Federation of Hemophilia (WFH) have set April 17, 2023 as World Hemophilia Day. The theme of the event this year is “Access for All: Prevention of bleeds as the global standard of care”. Building on last year’s theme, the call to action for the community in...